Erik A.C. Wiemer

10.4k citations

158 papers · 8.2k indexed · h-index 50

Molecular Biology top 1%
Oncology top 1%
Cancer Research top 0.5%
Pulmonary and Respiratory Medicine top 2%
Hematology top 1%

Co-authors: Ron H.J. Mathijssen Jaap Verweij Herman Burger Pieter Sonneveld Antonius W.M. Boersma Stefan Sleijfer Marieke H. Mossink Kees Nooter
Topics: Drug Transport and Resistance Mechanisms (24 papers)MicroRNA in disease regulation (19 papers)Cancer Treatment and Pharmacology (15 papers)
Cited by: Cancer Research Oncology Molecular Biology
Journals: Science Proceedings of the National Academy of Sciences Journal of Biological Chemistry
Partner nations: Netherlands United States Belgium

In The Last Decade

Erik A.C. Wiemer

156 papers receiving 8.1k citations

Peers

Countries citing papers authored by Erik A.C. Wiemer

Since Specialization

Citations

This map shows the geographic impact of Erik A.C. Wiemer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik A.C. Wiemer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik A.C. Wiemer more than expected).

Fields of papers citing papers by Erik A.C. Wiemer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik A.C. Wiemer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik A.C. Wiemer. The network helps show where Erik A.C. Wiemer may publish in the future.

Co-authorship network of co-authors of Erik A.C. Wiemer

This figure shows the co-authorship network connecting the top 25 collaborators of Erik A.C. Wiemer. A scholar is included among the top collaborators of Erik A.C. Wiemer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik A.C. Wiemer. Erik A.C. Wiemer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PL02.2.A TRAMETINIB IN NEUROFIBROMATOSIS TYPE 1 RELATED SYMPTOMATIC PLEXIFORM NEUROFIBROMAS: ONE-YEAR FOLLOW-UP OF THE TRAIN STUDY 2024 ·Neuro-Oncology ·(unknown),(unknown),Pim J. French,Erik A.C. Wiemer,(unknown),Olivier C. Manintveld,Walter Taal	0
2	Major vault protein (MVP) suppresses aging- and estrogen deficiency-related bone loss through Fas-mediated apoptosis in osteoclasts 2023 ·Cell Death and Disease ·Ruobing Wang,Yan Yang,Zhong‐Yin Zhang,Na Zhao,Erik A.C. Wiemer,Jingjing Ben,Junqing Ma,(unknown)	10
3	miR-196b-5p and miR-107 Expression Differentiates Ocular Sebaceous Carcinoma from Squamous Cell Carcinoma of the Conjunctiva 2022 ·International Journal of Molecular Sciences ·(unknown),(unknown),(unknown),Dion Paridaens,Erik A.C. Wiemer,Robert M. Verdijk	4
4	Cell-type-specific role of CHK2 in mediating DNA damage-induced G2 cell cycle arrest 2020 ·Oncogenesis ·Marijn T. M. van Jaarsveld,(unknown),Diana Ordoñez‐Rueda,Malte Paulsen,Erik A.C. Wiemer,Zhike Zi	30
5	Major vault protein suppresses obesity and atherosclerosis through inhibiting IKK–NF-κB signaling mediated inflammation 2019 ·Nature Communications ·Jingjing Ben,Bin Jiang,Dongdong Wang,Qingling Liu,Yongjing Zhang,Yu Qi,Tong Xing,Lili Chen,Xianzhong Liu,Yan Zhang,Xudong Zhu,Xiaoyu Li,Hanwen Zhang,Hui Bai,Qing Yang,Junqing Ma,Erik A.C. Wiemer,Yong Xu,Qi Chen	101
6	Aberrant MicroRNA Expression and Its Implications for Uveal Melanoma Metastasis 2019 ·Cancers ·Kyra N. Smit,Jiang Chang,Kasper Derks,Jolanda Vaarwater,(unknown),Robert M. Verdijk,Erik A.C. Wiemer,Hanneke W. Mensink,Joris Pothof,Annelies de Klein,Emine Kılıç	31
7	Tissue-Specific Chk1 Activation Determines Apoptosis by Regulating the Balance of p53 and p21 2019 ·iScience ·Marijn T. M. van Jaarsveld,(unknown),Erik A.C. Wiemer,Zhike Zi	9
8	Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β-catenin mutations 2018 ·European Journal of Surgical Oncology ·Milea J. M. Timbergen,M. Janssen,Cornelis Verhoef,Dirk J. Grünhagen,Frédéric Chibon,Marcel Smid,Stefan Sleijfer,Erik A.C. Wiemer	4
9	MiR-193b promotes autophagy and non-apoptotic cell death in oesophageal cancer cells 2016 ·BMC Cancer ·(unknown),Tracey R. O’Donovan,Antonius W.M. Boersma,Erik A.C. Wiemer,Sharon L. McKenna	49
10	Phase I Study of RGB-286638, A Novel, Multitargeted Cyclin-Dependent Kinase Inhibitor in Patients with Solid Tumors 2014 ·Clinical Cancer Research ·(unknown),Herman Burger,Peter de Bruijn,C. B. H. W. Lamers,Nicole C. Naus,Hannes Loferer,Erik A.C. Wiemer,Ron H.J. Mathijssen,Maja J.A. de Jonge	27
11	Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors 2013 ·Clinical Cancer Research ·Ferry A.L.M. Eskens,Francisco Javier Ramos,Herman Burger,James P. O’Brien,Adelaida Piera,Maja J.A. de Jonge,Yoshiharu Mizui,Erik A.C. Wiemer,(unknown),José Baselga,Josep Tabernero	195
12	CYP3A422* Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity 2013 ·Clinical Cancer Research ·Anne‐Joy M. de Graan,Laure Elens,Jason A. Sprowl,Alex Sparreboom,Lena E. Friberg,Bronno van der Holt,Pleun J. de Raaf,Peter de Bruijn,Frederike K. Engels,Ferry A.L.M. Eskens,Erik A.C. Wiemer,Jaap Verweij,Ron H.J. Mathijssen,Ron H. N. van Schaik	91
13	Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy 2012 ·Clinical Cancer Research ·Anne‐Joy M. de Graan,Walter J. Loos,Lena E. Friberg,Sharyn D. Baker,Jessica M. van der Bol,Leni van Doorn,Erik A.C. Wiemer,Bronno van der Holt,Jaap Verweij,Ron H.J. Mathijssen	29
14	A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients 2012 ·Clinical Cancer Research ·Karel Eechoute,Martin N. Fransson,(unknown),Floris A. de Jong,Alex Sparreboom,Winette T.A. van der Graaf,Lena E. Friberg,Gaia Schiavon,Erik A.C. Wiemer,Jaap Verweij,Walter J. Loos,Ron H.J. Mathijssen,Ugo De Giorgi	87
15	Correction: Recruitment of the Major Vault Protein by InlK: A Listeria monocytogenes Strategy to Avoid Autophagy 2011 ·PLoS Pathogens ·Laurent Dortet,Serge Mostowy,Ascel Samba‐Louaka,Edith Gouin,Marie‐Anne Nahori,Erik A.C. Wiemer,Olivier Dussurget,Pascale Cossart	23
16	A CYP3A4 Phenotype–Based Dosing Algorithm for Individualized Treatment of Irinotecan 2010 ·Clinical Cancer Research ·Jessica M. van der Bol,Ron H.J. Mathijssen,Geert-Jan Creemers,André Planting,Walter J. Loos,Erik A.C. Wiemer,Lena E. Friberg,Jaap Verweij,Alex Sparreboom,Floris A. de Jong	50
17	Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics. 2002 ·PubMed ·Marieke H. Mossink,Arend van Zon,(unknown),Martijn Schoester,Valerie A. Kickhoefer,George L. Scheffer,Rik J. Scheper,Pieter Sonneveld,Erik A.C. Wiemer	75
18	Up-Regulation of Drug Resistance-Related Vaults During Dendritic Cell Development 2002 ·The Journal of Immunology ·Anouk B. Schroeijers,Anneke W. Reurs,George L. Scheffer,Anita G.M. Stam,Mariska C. de Jong,Thomas Rustemeyer,Erik A.C. Wiemer,Tanja D. de Gruijl,Rik J. Scheper	49
19	The Mr 193,000 vault protein is up-regulated in multidrug-resistant cancer cell lines. 2000 ·PubMed ·(unknown),(unknown),(unknown),de Jong,(unknown),(unknown),(unknown),(unknown),Erik A.C. Wiemer,(unknown),Leonard H. Rome,(unknown)	43
20	Phylogenetic Analysis Based On Glycolytic-enzymes 1992 ·DIAL (Catholic University of Leuven) ·Paul A.M. Michels,Fred R. Opperdoes,Véronique Hannaert,Erik A.C. Wiemer,(unknown),Nathalie Chevalier	8

About Erik A.C. Wiemer

Erik A.C. Wiemer is a scholar working on Gastroenterology, Cancer Research and Oncology, having authored 158 papers that have together received 8.2k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (24 papers), MicroRNA in disease regulation (19 papers) and Cancer Treatment and Pharmacology (15 papers). The work is most often cited by research in Cancer Research (2.1k citations), Oncology (2.4k citations) and Molecular Biology (4.8k citations). Erik A.C. Wiemer has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include Ron H.J. Mathijssen, Jaap Verweij, Herman Burger, Pieter Sonneveld, Antonius W.M. Boersma, Stefan Sleijfer, Marieke H. Mossink, Kees Nooter, Walter J. Loos and Rik J. Scheper. Their work appears in journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact